Novo Nordisk

Danish pharma; GLP-1 originator (Ozempic 2017, Wegovy 2021). CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Diabetes care leader; Novo Holdings acquired Catalent in 2024 to expand fill-finish capacity.